Page 6 - Neoadjuvant Resectable News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Neoadjuvant resectable. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Neoadjuvant Resectable Today - Breaking & Trending Today

Surgery Is Falling Out of Favor in Rectal Cancer

With organ preservation on the rise, investigators say practice guidelines need to catch up. ....

University Of Rochester , New York , United States , Anthony Loria , National Cancer Database , National Comprehensive Cancer Network , Colorectal Cancer , Malignant Rectal Neoplasm , Rectal Cancer , Ancer Rectal , Alignant Neoplasia , Morgan Preservation , Clinical Guidelines ,

Metastatic NSCLC (mNSCLC) Biomarkers and Prognostic Factors Compared to Early-Stage NSCLC

Specialists review specific prognostic factors and biomarkers that help guide treatment selection for patients with metastatic NSCLC (mNSCLC) and discuss if these biomarkers differ from those observed in early-stage NSCLC. ....

David Carbone , Martin Dietrich , Non Small Cell Lung Cancer , Prognostic Factors , Treatment Selection , Early Stage Nsclc , Pd L1 Gt 50 , Pd L1 Lt 49 , Pl L1 Lt 1 ,

Omitting Surgery May Be Safe in Early BC After pCR

A small trial has helped to further identify women who can safely skip surgery after neoadjuvant therapy for early breast cancer. ....

United States , Henrym Kuerer , Ava Kwong , National Cancer Institute , European Society For Medical Oncology , Md Anderson Cancer Center , University Of Hong Kong , Cancer Center , European Society , Medical Oncology , Hong Kong , National Cancer , Breast Cancer , Alignant Breast Neoplasm , Breast Surgery , Alignant Neoplasia , Genomic Medicine , Edicine Genomic , Polymerase Chain Reaction , Circulating Tumor Cells Ctcs , Genetic Testing ,

Enhancing NSCLC Neoadjuvant Therapy

A panel deliberates post-neoadjuvant strategies and data requirements for optimizing immune checkpoint inhibitors in NSCLC neoadjuvant therapy. ....

David Carbone , Martin Dietrich , Patrick Forde , Non Small Cell Lung Cancer , Advanced Disease , Early Stage Disease , Post Op Setting , Novel Agent , Targeted Therapy , Trio Therapy ,

Neoadjuvant, Adjuvant, or Both? The Debate in NSCLC Rages On

The question of whether to give upfront immunochemotherapy in resectable non–small cell lung cancer, wait until after surgery, or give both remains a hot topic of debate. ....

Comunidad Autonoma De Cataluna , United States , Svizzera Italiana , Tony Sk Mok , Zofia Piotrowska , Enriqueta Felip , Silke Gillessen , Federico Cappuzzo , Rafal Dziadziuszko , University Of Gdansk , Department Of Oncology , Department Of Medical Oncology , European Society For Medical Oncology , Hebron University Hospital , Hospital Cancer Center , Department Of Clinical Oncology , Chinese University Of Hong Kong , European Society , Medical Oncology , Medscape Medical , Lung Cancer Unit , Medical University , Clinical Oncology , Chinese University , Massachusetts General Hospital Cancer Center , Non Small Cell Lung Cancer ,